Reprint

Latest Research in Post-COVID (Long COVID): Pathological and Treatment Studies of Sequelae and Complications

Edited by
July 2024
210 pages
  • ISBN978-3-7258-1505-0 (Hardback)
  • ISBN978-3-7258-1506-7 (PDF)
https://doi.org/10.3390/books978-3-7258-1506-7 (registering)

This book is a reprint of the Special Issue Latest Research in Post-COVID (Long COVID): Pathological and Treatment Studies of Sequelae and Complications that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

The coronavirus disease, 2019 (COVID-19), has led to the worst worldwide healthcare outbreak of the current century. Our knowledge on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus), the agent causing COVID-19, has dramatically increased in recent years. Further, healthcare systems are facing another outbreak due to COVID-19—long COVID or post-COVID-19 syndrome—which is the presence of long-lasting symptoms after an acute SARS-CoV-2 infection. The development of long-lasting post-COVID-19 symptoms has been called long COVID or a post-COVID-19 condition. To date, more than 100 potential long-lasting post-COVID symptoms have been potentially attributed to SARS-CoV-2. This Special Issue of Biomedicines, entitled "Latest Research in Post-COVID-19 (long COVID-19): Pathological and Treatment Studies of Sequelae and Complications”, has focused on potential gaps in our knowledge regarding the identification, timeframe, mechanisms, and treatment strategies for the management of the post-COVID-19 condition. The fourteen published papers in this Special Issue cover the following topics: 1, treatment of the post-COVID-19 condition; 2, neonatal repercussion of the SARS-CoV-2 infection; 3, risk factors of severe COVID-19; 4, phenotyping of post-COVID-19 pain; and 5, others.

Format
  • Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
COVID-19; SARS-CoV-2; pregnancy; vertical mother-to-child transmission; breast milk; vaccination; COVID-19; post-COVID; nociplastic pain; neuropathic pain; musculoskeletal pain; precision medicine; peripheral sensitization; central sensitization; nociceptive; CKD; COVID-19; GDF-15; mortality; SARS-CoV-2 infection; severe COVID-19; alpha-1 antitrypsin deficiency; genetic mutations; COVID-19; SARS-CoV-2; coronavirus disease 2019; exercise capacity; rehabilitation; palmitoylethanolamide (PEA); Luteolin; CoUltraPEALut; SARS-CoV-2; COVID-19; Post-Covid Olfactory Dysfunction (PCOD); respiratory disorders; COVID-19; pulmonary rehabilitation; exercise; physical exercise; post-COVID-19; fatigue; dyspnea; respiratory exercise; multidisciplinary rehabilitation; obesity; personalized rehabilitation; post-COVID-19 condition; rehabilitation; whole-body cryostimulation; COVID-19; neonates; gastrointestinal malformations; congenital anomalies; long COVID; COVID-19; PASC-CVS; cardiac magnetic resonance imaging; CMR; myopericarditis; chronic pericardial effusion; long COVID; red blood cells; nucleotides; microcirculation; endothelium; Long COVID; fatigue; dyspnea; cortisol; adrenal insufficiency; immune cells; inflammation; idiopathic pulmonary fibrosis; post-COVID pulmonary fibrosis; immune cells; immune checkpoint; CD4; CD8; NK; PD-1; TIGIT; n/a